問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Radiation Therapy

Division of Radiology

Division of Hematology & Oncology

更新時間：2023-09-19

湯禹舜
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

湯禹舜

List

17Cases

2020-09-01 - 2027-06-30

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    AtezolizumabTiragolumab

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-09-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Tiragolumab ；Atezolizumab

Participate Sites
4Sites

Recruiting4Sites

2020-08-31 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma(ESCC)

  • Test Drug

    Durvalumab

Participate Sites
11Sites

Recruiting11Sites

2017-08-10 - 2025-01-09

Phase III

Completed
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

  • Test Drug

    Injection Injection

Participate Sites
12Sites

Recruiting12Sites

2022-05-20 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-06-01 - 2024-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-06-01 - 2024-04-08

Phase III

Completed
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)

  • Condition/Disease

    Advanced/Metastatic Esophageal Carcinoma

  • Test Drug

    Keytruda

Participate Sites
10Sites

Terminated9Sites

林振源
China Medical University Hospital-Taipei

未分科

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2018-07-03 - 2020-08-31

Phase III

Completed
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
8Sites

Terminated7Sites

林振源
China Medical University Hospital-Taipei

未分科

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-06-01 - 2024-09-30

Phase III

Completed
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy and safety of tislelizumab (BGB-A317) in combination with chemotherapy as first-line treatment in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Condition/Disease

    unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Test Drug

    BGB-A317

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

林振源
China Medical University Hospital

Division of Hematology & Oncology

2022-06-01 - 2024-10-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB